Abstract
Introduction

21
Radiation induced thyroid cancer remains an important clinical concern. Although the medical 22 use of radiation for treating benign head and neck conditions has been abandoned, the risks 23 associated with the use of such treatments in the middle of last century persists for decades 24 after the exposure; currently, radiation is frequently used to treat children with cancer and, as 25 of 2013, over 400,000 survivors are alive in the U.S.; and nuclear accidents, such as those at 26 Chernobyl and Fukushima, remain possible (Sinnott et al. 2010 ,Wheatley et al. 2017 . In 2006, Haymart et al. 2008 ,Witczak et al. 2016 . In contrast, in a case-control analysis matching 35 thyroid cancer cases with controls nested in the European Prospective Investigation into Cancer 36 and Nutrition cohort (EPIC) study, Rinaldi et al. found that thyroid cancer risk was negatively 37 associated with the TSH levels (Rinaldi et al. 2014) . In addition, the EPIC study found that high 38 thyroglobulin (Tg) levels preceded the diagnosis of thyroid cancer by almost a decade. The 39 predictive value of these biomarkers in radiation-exposed individuals has not yet been 40 determined. 41 The objective of the current analysis was to evaluate the predictive value of baseline TSH and 42 Tg levels for the development of thyroid nodules and cancer in radiation-exposed patients. The 43 study is based on a cohort of subjects irradiated for benign conditions in the head and neck 44 area and examined in 1974, both at Michael Reese Hospital in Chicago, and followed 45 prospectively thereafter. We performed a cross-sectional analysis using the presence or 46 absence of nodules and cancer found at the 1974 examinations (prevalent cases) and a 47 longitudinal study of nodules and cancers that developed during the follow-up of subjects 48 whose initial examination was normal (incident cases).
49
Patients and Methods
50
Radiation exposed cohort 51 The cohort consisted of 4296 subjects who were younger than 16 years when they were treated 52 with radiation to the head and neck region for benign conditions from of plasma TSH, plasma Tg levels, anti-Tg antibodies and thyroid imaging (Favus et al. 1976 ).
66
Imaging in 1974 consisted of thyroid scanning using Tc-pertechnetate with a pinhole collimator 67 to obtain anterior and oblique images. Any nodule with uptake higher than the surrounding 68 thyroid was considered "hot." When a "hot" nodule was seen, the scan was repeated using 123 I.
69
Isotopic scans were replaced by thyroid ultrasonography when it became available years later.
70
Of the 424 subjects with recorded follow-up, 72 of them had a total of 147 thyroid ultrasound 71 examinations performed. When the scan findings were considered "uncertain," the subject was 72 asked to return in six months for a repeat evaluation. When nodules were detected, subjects 73 were referred to their physicians for management.
74
Laboratory tests
75
A modification of the assay using NIH provided reagents was used to ascertain plasma TSH, as 76 previously described (Schneider et al. 1977 ,Frohman et al. 1982 . Contemporaneously, the 77 upper limit of normal was reported as 6 mIU/L with a sensitivity of 0.5-1.0 mIU/L and, later, the 78 intra-and inter-assay coefficients were reported to be 7.2% and 11.9%, respectively (Schneider 79 et al. 1977 ,Williams et al. 1988 . The Tg assay was performed using a modification of the 80 radioimmunoassay first described by Van Herle et al. (Van Herle et al. 1973,Schneider et al. 81 1977). The least detectable concentration was 0.8 ng/ml. Determination of the Tg level in the 82 plasma and serum gave identical results. The within assay coefficient of variation was 5.2% and 83 between assay coefficient of variation was 12.8% for the range of 3.5-36ng/ml. Samples 84 resulting in greater than an 85% displacement of the tracer were diluted and re-assayed. Tg antibody levels were measured using a tanned erythrocyte agglutination kit as previously 86 described (Schneider et al. 1977 
Results
125
Cross-Sectional study
Based on their physical examination and Tc-pertechnetate and, when indicated 123 I, thyroid 127 scan the 806 subjects were categorized as follows: 547 were normal, 186 were abnormal, 68 128 were uncertain, and 5 had hot nodules. Of the 68 subjects whose result was uncertain, 49 were 129 reevaluated on follow-up visits within one year when 13 continued to be classified as uncertain, Similarly, analyses of subjects with benign nodules excluded those with malignant ones.
139
(i) Relationship between TSH and Tg levels and prevalent thyroid nodules. The group of subjects 140 with nodules was compared to the group with normal examination findings (Table 1) . For TSH 141 levels there was no significant difference between the groups (2.30 mIU/L vs 2.34 mIUI/L; 142 p=0.55). The dose to the thyroid gland was significantly higher in subjects with nodules (65. 2 143 cGy vs 55.6 cGy, p<0.001). Tg levels at baseline were also significantly higher in the group with 144 nodules (26.1 ng/mL vs 9.37 ng/mL; p<0.001). In multivariate logistic models both dose to the 145 thyroid gland and Tg level remained significant (p= 0.016 and p<0.001, respectively). shows the ROC curve for Tg levels and the presence of nodules at the time of Tg measurements.
147
The area under the curve for this cross-sectional analysis was 0. nodules. As a result of findings at the first visit 174 subjects had surgery within one year.
153
Cancers were found in 55 of these subjects and benign nodules in 119 of them (Table 1 ). There 154 was no difference between the TSH levels of subjects with benign and malignant nodules (2.25 155 mIU/L vs 2.06 mIUI/L; p=0.41) ( Figure 3A) . Similarly, there was no difference in Tg levels 156 between the subjects in these two groups (25.1 ng/ml vs 27.1 ng/mL; p=0.66), although the Tg 157 levels in both of these groups were higher than the Tg levels in those with a normal exam (9.37 158 ng/ml; p<0.001 for both comparisons). When 26 of the cancers ≤10 mm were excluded, the 159 findings remained the same. We also examined whether there was a correlation between TSH 160 and Tg levels and thyroid cancer size in the 55 subjects with thyroid cancer. Neither coefficient 161 was significant; 0.087 for TSH (p=0.522) and 0.001 for Tg (p=0.993). (Table 2 ). There was no difference comparing the TSH levels for these two groups (2.3 mIU/L vs 181 2.2 mIU/L; p=0.77) ( Figure 3B ). When the Tg levels at the initial visit were compared between 182 the two groups, the baseline Tg levels in those who subsequently developed thyroid nodules 183 were significantly higher (11.2 ng/mL vs 8.8 ng/mL; p=0.017), compared to those who remained In order to take into account the longer observation time for the subjects who did not develop 189 nodules, proportional hazards (Cox) analysis was performed (Table 3) (Table 3) .
197
Relationship between initial TSH and Tg levels and whether an incident nodule was malignant.
198
When initial visit TSH and Tg levels were compared between the benign and malignant groups, 199 no significant differences were found (p=0.21 and p=0.83 respectively (Fig 2 B and Table 2 ). This study shows an increased risk of developing thyroid nodules in radiation exposed subjects 209 with higher baseline Tg levels. Serum Tg level has been associated with several thyroid 210 disorders, but its utility as a predictor of thyroid cancer risk has not been firmly established for either sporadic or radiation induced thyroid cancer. The potential role of Tg as a predictor of 212 the subsequent development of sporadic thyroid cancer is clearest in the EPIC cohort study 213 (Rinaldi et al. 2014) and in an earlier, smaller study (Thoresen et al. 1988 (Rinaldi et al. 2014) . The data linking Tg levels with thyroid nodules and cancer in 217 radiation exposed subjects are limited. We previously reported that thyroglobulin levels 218 increased over time in subjects who developed thyroid nodules (Schneider et al. 1985) . We 219 also found an association between Tg levels and the absolute number, but not the total volume 220 of thyroid nodules detected by ultrasound (Schneider et al. 1977 ). The current study shows a 221 positive association between baseline serum Tg levels and the presence or absence of thyroid 222 nodules in a large cohort of radiation-exposed subjects. Interestingly, this association was 223 demonstrated both at the time of the measurement (the cross-section analysis) and 224 longitudinally over more than two decades of follow-up. In the cross-sectional analysis, subjects 225 with abnormal exams had significantly higher baseline Tg levels and also received a higher 226 radiation dose (Table 1 ). The mean baseline Tg levels were found to be significantly elevated in 227 subjects with nodular thyroid disease, both benign and malignant compared to normal 228 individuals, but the Tg levels were not different comparing subjects with benign to those with 229 malignant thyroid nodules.
230
In subjects whose initial examination was normal, Tg levels and a younger age at the time of the 231 radiation treatment were risk factors for subsequent development of thyroid nodules during 232 follow-up (Table 2) . Even though higher baseline Tg levels were able to predict development of thyroid nodules, they did not differentiate between the benign and malignant ones. Subjects in positive associations between TSH levels and the probability that a nodule is malignant. The 253 majority of evidence appears to be that the higher the TSH level, even within the normal range, 254 the higher the risk that a nodule is malignant. Numerous studies have shown the trophic effect 255 of TSH on sporadic thyroid cancer growth (Ichikawa et al. 1976,Carayon et al. 1980) and 256 suppression has been shown to improve relapse free survival (Pujol et al. 1996) . Boelaert et al. 257 found in non-radiation exposed patients that the risk of malignancy rose in parallel with serum 258 TSH levels, especially when the TSH level was great than 1.8 mU/liter (Boelaert et al. 2006 ).
259
Several other retrospective studies produced similar findings (Haymart et al. 2008,Witczak et al. 260 2016), but others showed opposing results (Castro et al. 2011 ,Kim et al. 2011 . In a recent the TSH levels were associated with the risk of thyroid nodules or cancer (Cahoon et al. 2013 ).
276
Our results show no association between pre-diagnostic TSH levels and the risk that a nodule is 277 malignant in radiation exposed subjects. In addition, there were no association between the 278 baseline TSH levels and the risk of developing thyroid nodules or cancer during the follow-up 279 period. This difference could potentially be due to the carcinogenic effect of radiation having a 280 larger effect on the development of thyroid nodules and cancer than TSH levels. The dose-281 response relationship is well documented, with the excess risk remaining elevated at least to 40 282 years (Schneider et al. 1993 ,Ron et al. 1995 ,Veiga et al. 2016 ). An observation that supports with autonomously functioning "hot" nodules (Satta et al. 1993) . Further, the EPIC study found 291 a significant negative association between TSH and thyroid cancer with an odds ratio 0.56.
292
Similarly, and more recently, baseline findings from the Fukushima Health Management Survey 293 indicated an association between lower TSH levels and the presence of thyroid nodules and 294 papillary thyroid cancer (Suzuki et al. 2016a) in children who were exposed to radiation during 295 the nuclear accident. Some authors suggest that a genetic predisposition could explain these 296 results (Rinaldi et al. 2014) . Genome wide association studies identified several genetic variants 297 (e.g. 9q22.23 and 14q13.3) associated with both differentiated thyroid cancer and low TSH 298 values (Gudmundsson et al. 2009 ,Gudmundsson et al. 2012 . Also, the association with variants on 9q22.33 has been demonstrated in radiation-induced thyroid cancer (Takahashi et al. 2010). 300 It is unknown if subjects in our cohort had such genetic predispositions which could have 301 further influenced TSH levels. (Schneider AB et al. 1993) . Anti-TPO antibodies (known as anti-microsomal antibodies in 1974) 317 were not measured as thyroid nodules and thyroid cancer were the two endpoints of the study. Anti-Tg levels were measured as these antibodies were known to interfere with the 319 thyroglobulin measurements (Schneider AB et al. 1978) . Tg not included in the presence and anti-Tg antibodies in 9, 8, 1 and 0 in nodule-free, developed nodules, cancer and benign subjects, respectively. 2 Reduced to 139 subject developed nodules and 268 did not due to measurable anti-Tg levels.
3 Reduced to 121 subjects with nodules and 238 without due to missing dose estimates.
